ClinicalTrials.gg
Active, not recruitingNCT04884360MONO-OLA1Updated Mar 2, 2026

D9319C00001- 1L OC Mono Global RCT

A Phase 3 interventional study of Olaparib and Matching placebo in Ovarian Cancer, sponsored by AstraZeneca. Active, not recruiting at 89 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.

Enrollment
9th of 69
366 · median 97
Started
2021
with 3 others
Phase 3
16 of 69
2 open now
Primary completion
2026-07
later than 11 of 25 live
Registered
50th of 69
by date
Lead sponsor
21 of 69
AstraZeneca

Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 9th largest by enrollment, is one of 4 that started in 2021, is one of 16 in phase 3, reaches primary completion later than 11 of the 25 other live ones, and was the 50th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing olaparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high grade serous or endometroid ovarian cancer (including fallopian tube cancer or primary peritoneal cancer) who are in complete or partial response following treatment with standard first-line platinum-based chemotherapy.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

Keywords

  • BRCA Wild Type;
  • Double-blind;
  • Randomized;
  • Placebo-controlled;
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants must be ≥18 years at the time of (pre-)screening
  2. Histological and staging criteria:Female participants who must have histologically newly diagnosed high-grade serous or high-grade endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that is Stage III or IV according to the International FIGO 2014.
  3. Participants are eligible if they fulfil any of the following surgical criteria:

    • Stage III: primary debulking surgery with macroscopic residual disease post-surgery, chemotherapy, or inoperable.
    • Stage IV: primary debulking surgery regardless of residual disease, neoadjuvant chemotherapy, or inoperable.
  4. Chemotherapy criteria:

    • Participants must have received platinum-based chemotherapy consisting of a minimum of 6 treatment cycles and a maximum of 9, however, if platinum-based therapy must be discontinued early as a result of toxicities specifically related to the platinum regimen, participants must have received a minimum of 4 cycles of the platinum regimen.
    • Participants must have, in the opinion of the investigator, clinical CR or PR as per 1.1 criteria with no > 2 cm on the post-treatment scan and have no clinical evidence of disease progression or a rising CA-125 level (see inclusion criterion 5), following completion of this chemotherapy course.
    • A participant who received interval debulking surgery must have had ≥ 2 postoperative cycles of platinum-based therapy.
  5. Participants must meet one of the criteria specified below for pre-treatment CA-125 measurements as follows:

    • CA-125 in the normal range or
    • CA-125 decrease by ≥ 90% during their front-line therapy that is stable for at least 7 days (ie, no increase > 15% from nadir). During screening, if the first CA-125 value is greater than the (ULN), a second assessment must be performed at least 7 days after the first. If the second assessment is > 15% more than the first value, the participant is not eligible).
  6. Participants should not have received bevacizumab with chemotherapy or be planned to receive bevacizumab maintenance therapy.
  7. Participants must be randomised within a maximum of 12 weeks from the last day of chemotherapy infusion (but no earlier than 3 weeks).

8. performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to randomisation.

9, Provision, at pre-screening, of a formalin-fixed, paraffin-embedded (FFPE) tumour sample to assess tBRCA status and for HRD testing centrally. The centrally performed tBRCA test results must be available prior to randomisation and must indicate that the participant has a BRCAwt tumour, defined by the absence of a deleterious or suspected deleterious BRCA mutation by central testing.

10, Adequate organ and marrow function.

Key Exclusion Criteria:

  • 1, Participants with stable disease or progressive disease on the post-treatment scan or clinical evidence of progression at the end of the participant's first-line chemotherapy treatment, or any evidence of progressive disease prior to randomization.

    2, Participant has mucinous or clear cell subtypes of epithelial ovarian cancer, carcinosarcoma, undifferentiated ovarian cancer, non-epithelial ovarian cancer, borderline tumours or low grade epithelial ovarian tumours (applies to fallopian tube and primary peritoneal tumours where applicable).

    3, Participants with Stage III disease who have had complete cytoreduction (ie, no macroscopic residual disease) at their primary debulking surgery.

    4, Participants who have undergone ˃ 2 debulking (cytoreductive) surgeries.

    5, History of another primary except for: malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention and of low potential risk for recurrence; Adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), and Stage 1, Grade 1 endometrial carcinoma. Participants with a history of localised triple negative breast cancer, provided they completed their adjuvant chemotherapy more than three years prior to registration, and that the participant remains free of recurrent or disease.

    6, Persistent toxicities ( Grade ≥2) caused by previous anticancer therapy, excluding alopecia and CTCAE Grade 2 peripheral neuropathy. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included after consultation with the AstraZeneca study physician.

    7, Participant is

    8, Prior exposure to a PARP inhibitor, including olaparib

    9, Any concurrent anticancer treatment

    10, Currently pregnant or breast-feeding

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
366 participants (actual)

Study arms

  • Experimental
    Group A: Olaparib tablets 300 mg oral twice daily (n=238).

    Participants in Group A will receive olaparib tablets taken orally at a dose of 300 mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator, whichever is earlier, and as long as in the investigator's opinion they are benefiting from treatment and do not meet any other discontinuation criteria.

    Drug: Olaparib

  • Placebo comparator
    Group B: Placebo tablets 300 mg oral twice daily (n=118)

    Participants in Group B will receive matching placebo tablets taken orally at a dose of 300 mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator, whichever is earlier, and as long as in the investigator's opinion they are benefiting from treatment and do not meet any other discontinuation criteria.

    Other: Matching placebo

Interventions

  • Olaparib tablets 300 mg oral twice daily

  • OtherMatching placebo

    Matching placebo tablets taken orally at a dose of 300 mg twice daily

06

What researchers measure

Primary outcomes

  1. Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS in participants with Stage III/IV ovarian cancer with a BRCAwt HRD positive tumour and a CR/PR following standard 1st line platinum based chemotherapy treatment.

    PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by the investigator at the local site, or death due to any cause.

    Time frame: Approximately 3 years

  2. Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS in participants with Stage III/IV ovarian cancer with a BRCAwt tumour and a CR/PR following standard 1st line platinum-based chemotherapy treatment.

    PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by the investigator at the local site, or death due to any cause.

    Time frame: Approximately 3 years

Secondary outcomes

  1. Superiority of olaparib as maintenance treatment relative to placebo by assessment of OS in participants with Stage III/IV ovarian cancer with a BRCAwt HRD positive tumour and a CR/PR following standard first line platinum based chemotherapy treatment.

    OS is defined as time from randomisation until the date of death due to any cause.

    Time frame: Approximately 4 years

  2. Superiority of olaparib as maintenance treatment relative to placebo by assessment of OS in participants with Stage III/IV ovarian cancer with a BRCAwt tumour and a CR/PR following standard first-line platinum-based chemotherapy treatment.

    OS is defined as time from randomisation until the date of death due to any cause.

    Time frame: Approximately 4 years

  3. Superiority of olaparib as maintenance treatment relative to placebo by assessment of TFST in participants with a BRCAwt HRD positive tumour and a CR or PR following standard first-line platinum-based chemotherapy treatment.

    TFST is defined as time from randomisation until the start date of the first subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause.

    Time frame: Approximately 4 years

  4. Superiority of olaparib as maintenance treatment relative to placebo by assessment of TFST in participants with a BRCAwt tumour and a CR or PR following standard first line platinum based chemotherapy treatment.

    TFST is defined as time from randomisation until the start date of the first subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause.

    Time frame: Approximately 4 years

  5. Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS2 in participants with a BRCAwt HRD positive tumour and a CR or PR following standard first-line platinum based chemotherapy treatment.

    PFS2 is defined as the time from the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death.

    Time frame: Approximately 4 years

  6. Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS2 in participants with a BRCAwt tumour and a CR or PR following standard first-line platinum based chemotherapy treatment.

    PFS2 is defined as the time from the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death.

    Time frame: Approximately 4 years

  7. Superiority of olaparib as maintenance treatment relative to placebo by assessment of TSST in participants with a BRCAwt HRD positive tumour and a CR or PR following standard first-line platinum based chemotherapy treatment.

    TSST is defined as time from randomisation until the start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause.

    Time frame: Approximately 4 years

  8. Superiority of olaparib as maintenance treatment relative to placebo by assessment of TSST in participants with a BRCAwt tumour and a CR or PR following standard first-line platinum based chemotherapy treatment.

    TSST is defined as time from randomisation until the start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause.

    Time frame: Approximately 4 years

  9. Superiority of olaparib as maintenance treatment relative to placebo by assessment of time to TDT in participants with a BRCAwt HRD positive tumour and a CR/PR following standard first-line platinum based chemotherapy treatment.

    TDT is defined as time from randomisation until discontinuation of treatment for any reason, including disease progression, toxicity and death.

    Time frame: Approximately 3 years

  10. To demonstrate superiority of olaparib as maintenance treatment relative to placebo by assessment of time to TDT in participants with a BRCAwt tumour and a CR or PR following standard first-line platinum based chemotherapy treatment.

    TDT is defined as time from randomisation until discontinuation of treatment for any reason, including disease progression, toxicity and death.

    Time frame: Approximately 3 years

  11. Superiority of olaparib as maintenance treatment relative to placebo by assessment of time to earliest progression by RECIST 1.1/CA 125/death in participants with a BRCAwt HRD positive tumour and a CR/PR following 1st line platinum based chemotherapy

    Time to earliest progression by RECIST 1.1/CA 125 or death will be measured from time of randomisation to the earlier date of RECIST 1.1/CA-125 progression or death by any cause.

    Time frame: Approximately 3 years

  12. Superiority of olaparib as maintenance treatment relative to placebo by assessment of time to earliest progression by RECIST 1.1/CA 125/death in participants with a BRCAwt tumour and a CR/PR following first-line platinum based chemotherapy.

    Time to earliest progression by RECIST 1.1 or CA 125 or death will be measured from time of randomisation to the earlier date of RECIST 1.1 or CA-125 progression or death by any cause.

    Time frame: Approximately 3 years

  13. Assess Health-related quality of life in participants treated with olaparib compared with placebo in participants with a BRCAwt HRD positive tumour and a CR or PR following standard first-line platinum based chemotherapy treatment

    Change from baseline in EORTC QLQ C30.

    Time frame: Approximately 3 years

  14. Assess Health-related quality of life in participants treated with olaparib compared with placebo in participants with BRCAwt tumour and a CR or PR following standard first-line platinum based chemotherapy treatment

    Change from baseline in EORTC QLQ C30.

    Time frame: Approximately 3 years

Other outcomes

  1. Assess the safety and tolerability of olaparib in terms of AEs/SAEs as compared with placebo in participants with a BRCAwt tumour and a CR or PR following standard first-line platinum-based chemotherapy treatment.

    Graded according to the National Cancer Institute (NCI CTCAE)

    Time frame: Approximately 3 years

07

Study locations

89 sites
  • Research Site
    Santiago, 8241479, Chile
  • Research Site
    Santiago, 8420383, Chile
  • Research Site
    Temuco, 4800827, Chile
  • Research Site
    Temuco, 4810218, Chile
  • Research Site
    Viña del Mar, 2540488, Chile
  • Research Site
    Baoji, 721008, China
  • Research Site
    Beijing, 100034, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chengdu, 610072, China
  • Research Site
    Chongqing, 400038, China
  • Research Site
    Chongqing, 400042, China
  • Research Site
    Guangzhou, 510095, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Guiyang, 550004, China
  • Research Site
    Haikou, 570311, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Hefei, 230601, China
  • Research Site
    Jiaxing, 314001, China
  • Research Site
    Jining, 272029, China
  • Research Site
    Lanzhou, 730030, China
  • Research Site
    Linyi, 276000, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Qingdao, 266034, China
  • Research Site
    Rui’an, 325200, China
  • Research Site
    Shanghai, 200011, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110042, China
  • Research Site
    Suzhou, 215004, China
  • Research Site
    Tianjin, 300050, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Ürümqi, 830000, China
  • Research Site
    Ürümqi, 830054, China
  • Research Site
    Wenzhou, 325027, China
  • Research Site
    Wenzhou, CN-325000, China
  • Research Site
    Wuhan, 430000, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuxi, 214062, China
  • Research Site
    Xuzhou, 221000, China
  • Research Site
    Xuzhou, 221009, China
  • Research Site
    Yanji, 133000, China
  • Research Site
    Zibo, 255200, China
  • Research Site
    Zunyi, 563100, China
  • Research Site
    Bogotá, 110221, Colombia
  • Research Site
    Bogotá, Colombia
  • Research Site
    Medellín, 50030, Colombia
  • Research Site
    Gurgaon, 122001, India
  • Research Site
    Jaipur, 302017, India
  • Research Site
    Kolkata, 700160, India
  • Research Site
    Madurai, 625107, India
  • Research Site
    Namakkal, 637001, India
  • Research Site
    Nashik, 422002, India
  • Research Site
    New Delhi, 110085, India
  • Research Site
    New Delhi, 11029, India
  • Research Site
    Arequipa, AREQUIPA01, Peru
  • Research Site
    Lima, 15036, Peru
  • Research Site
    Lima, LIMA 29, Peru
  • Research Site
    Lima, LIMA 34, Peru
  • Research Site
    San Isidro, 27, Peru
  • Research Site
    Arkhangelsk, 163045, Russia
  • Research Site
    Chelyabinsk, 454087, Russia
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Moscow, 117997, Russia
  • Research Site
    Saint Petersburg, 197758, Russia
  • Research Site
    Saint Petersburg, 198255, Russia
  • Research Site
    Tomsk, 634028, Russia
  • Research Site
    Yekaterinburg, 620905, Russia
  • Research Site
    Port Elizabeth, 6045, South Africa
  • Research Site
    Adana, 01120, Turkey (Türkiye)
  • Research Site
    Ankara, 06100, Turkey (Türkiye)
  • Research Site
    Ankara, 06800, Turkey (Türkiye)
  • Research Site
    Cordaleo, 35575, Turkey (Türkiye)
  • Research Site
    Istanbul, 34010, Turkey (Türkiye)
  • Research Site
    Samsun, 55139, Turkey (Türkiye)
  • Research Site
    Chernihiv, 14029, Ukraine
  • Research Site
    Dnipro, 49102, Ukraine
  • Research Site
    Ivano-Frankivsk, 76018, Ukraine
  • Research Site
    Kharkiv, 61103, Ukraine
  • Research Site
    Kryvyi Rih, 50048, Ukraine
  • Research Site
    Kyiv, 03022, Ukraine
  • Research Site
    Kyiv, 04050, Ukraine
  • Research Site
    Zaporizhzhya, Ukraine
  • Research Site
    Hanoi, 100000, Vietnam
  • Research Site
    Hà Nội, 100000, Vietnam
  • Research Site
    Ho Chi Minh City, 700000, Vietnam
  • Research Site
    Ho Chi Minh City, Vietnam
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Jul 2026, 61 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 61 months is above that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2021
First posted
May 13, 2021
StartActual
May 31, 2021
Primary completionEst.
Jul 27, 2026
CompletionEst.
Jul 27, 2027
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04884360
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 13, 2021
Start date
May 31, 2021
Primary completion
Jul 27, 2026 (estimated)
Completion
Jul 27, 2027 (estimated)
Last update
Mar 2, 2026

Study contacts

Xiaohua Wu
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion